{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:08:45Z","timestamp":1782346125253,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"DOI":"10.1186\/s12884-025-08420-3","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:34:47Z","timestamp":1764225287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world use of non-pregnancy-specific automated insulin delivery systems during gestation and delivery: a case series"],"prefix":"10.1186","volume":"25","author":[{"given":"Federica","family":"Carrieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pompea Antonia","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Coluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Centorame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Formoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"8420_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-8587(20)30427-7","volume":"9","author":"D Simmons","year":"2021","unstructured":"Simmons D. Adverse pregnancy outcomes in women with type 1 or type 2 diabetes. Lancet Diabetes Endocrinol. 2021;9:129\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8420_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2213-8587(20)30406-X","volume":"9","author":"HR Murphy","year":"2021","unstructured":"Murphy HR, et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year National population-based cohort study. Lancet Diabetes Endocrinol. 2021;9:153\u201364.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8420_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S2213-8587(23)00116-X","volume":"11","author":"K Benhalima","year":"2023","unstructured":"Benhalima K, et al. Management of type 1 diabetes in pregnancy: update on lifestyle, Pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol. 2023;11:490\u2013508.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8420_CR4","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/S0140-6736(17)32400-5","volume":"390","author":"DS Feig","year":"2017","unstructured":"Feig DS, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390:2347\u201359.","journal-title":"Lancet"},{"key":"8420_CR5","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.2337\/dc25-S007","volume":"48","author":"ADAPP Committee","year":"2025","unstructured":"Committee ADAPP, et al. Diabetes technology: standards of care in Diabetes\u20142025. Diabetes Care. 2025;48:S146\u201366. 7.","journal-title":"Diabetes Care"},{"key":"8420_CR6","unstructured":"Guidelines of the: Associazione dei Medici Diabetologi (AMD), Societ\u00e0 Italiana di Diabetologia (SID) and of the Societ\u00e0 Italiana di Endocrinologia e Diabetologia Pediatrica (SIEDP). Type 1 Diabetes Mellitus Therapy. 2024."},{"key":"8420_CR7","doi-asserted-by":"crossref","unstructured":"Committee ADAPP et al. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes\u20142025. Diabetes Care, 2025;48:S306\u2013S320.","DOI":"10.2337\/dc25-S015"},{"key":"8420_CR8","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593\u2013603.","journal-title":"Diabetes Care"},{"key":"8420_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1089\/dia.2021.0073","volume":"23","author":"D Tundidor","year":"2021","unstructured":"Tundidor D, et al. Continuous glucose monitoring Time-in-Range and HbA1c targets in pregnant women with type 1 diabetes. Diabetes Technol Ther. 2021;23:710\u20134.","journal-title":"Diabetes Technol Ther"},{"key":"8420_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1089\/dia.2021.0112","volume":"23","author":"G O\u2019Malley","year":"2021","unstructured":"O\u2019Malley G, et al. Longitudinal observation of insulin use and glucose sensor metrics in pregnant women with type 1 diabetes using continuous glucose monitors and insulin pumps: the LOIS-P study. Diabetes Technol Ther. 2021;23:807\u201317.","journal-title":"Diabetes Technol Ther"},{"key":"8420_CR11","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1056\/NEJMoa2303911","volume":"389","author":"TTM Lee","year":"2023","unstructured":"Lee TTM, et al. Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med. 2023;389:1566\u201378.","journal-title":"N Engl J Med"},{"key":"8420_CR12","unstructured":"FAQs -. CamAPS FX. Last access 20 Oct 2025 https:\/\/camdiab.com\/faq"},{"key":"8420_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/dia.2022.0540","volume":"25","author":"ED Szmuilowicz","year":"2023","unstructured":"Szmuilowicz ED, Levy CJ, Buschur EO, Polsky S. Expert guidance on Off-Label use of hybrid Closed-Loop therapy in pregnancies complicated by diabetes. Diabetes Technol Ther. 2023;25:363\u201373.","journal-title":"Diabetes Technol Ther"},{"key":"8420_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-8587(24)00089-5","volume":"12","author":"K Benhalima","year":"2024","unstructured":"Benhalima K, et al. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2024;12:390\u2013403.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8420_CR15","doi-asserted-by":"crossref","unstructured":"Azahaf S et al. Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial. EClinicalMedicine.\u00a02025;81.","DOI":"10.1016\/j.eclinm.2025.103106"},{"key":"8420_CR16","unstructured":"Donovan L.E. et al. Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy The CIRCUIT Randomized Clinical Trial. JAMA 2025."},{"key":"8420_CR17","doi-asserted-by":"crossref","unstructured":"Wang XS, Dunlop AD, McKeen JA, Feig DS, Donovan LE. Real-world use of Control-IQ\u2122 technology automated insulin delivery in pregnancy: A case series with qualitative interviews. Diabet Med. 2023;40.","DOI":"10.1111\/dme.15086"},{"key":"8420_CR18","first-page":"596","volume":"26","author":"C Quir\u00f3s","year":"2024","unstructured":"Quir\u00f3s C, et al. Real-World evidence of Off-Label use of commercially automated insulin delivery systems compared to multiple daily insulin injections in pregnancies complicated by type 1 diabetes. Diabetes Technol Ther. 2024;26:596\u2013606.","journal-title":"Diabetes Technol Ther"},{"key":"8420_CR19","doi-asserted-by":"crossref","unstructured":"Giannoulaki P, et al. Use of advanced hybrid Closed-Loop system during pregnancy: strengths and limitations of achieving a tight glycemic control. J Clin Med. 2024;13:1441.","DOI":"10.3390\/jcm13051441"},{"key":"8420_CR20","doi-asserted-by":"crossref","unstructured":"Battelino T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019; 42:1593\u20131603.","DOI":"10.2337\/dci19-0028"},{"key":"8420_CR21","unstructured":"WHO - Child growth standards. Last access 20 Oct 2025.\u00a0https:\/\/www.who.int\/tools\/child-growth-standards\/standards"},{"key":"8420_CR22","doi-asserted-by":"crossref","unstructured":"Stewart ZA et al. Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: A randomized controlled crossover trial. Diabetes Care,2018;41.","DOI":"10.2337\/dc17-2534"},{"key":"8420_CR23","doi-asserted-by":"crossref","unstructured":"Stewart ZA, et al. Closed-Loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med. 2016;375.","DOI":"10.1056\/NEJMoa1602494"},{"key":"8420_CR24","doi-asserted-by":"crossref","unstructured":"Murphy HR, et al. Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: A randomized crossover case series. Diabetes Care. 2011;34.","DOI":"10.2337\/dc11-1430"},{"key":"8420_CR25","doi-asserted-by":"crossref","unstructured":"Murphy HR, et al. Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes. Diabetes Care.\u00a02011;34:406\u201311.","DOI":"10.2337\/dc10-1796"},{"key":"8420_CR26","unstructured":"ClinicalTrials.gov. Published 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04902378,term=CIRCUIT."},{"key":"8420_CR27","first-page":"71","volume":"1","author":"KM Rasmussen","year":"2009","unstructured":"Rasmussen KM, Yaktine AL. Committee to reexamine IOM pregnancy weight Guidelines. Food and nutrition board, board on Children, youth and Families, Institute of medicine. Natl Res Council: Weight Gain Dur Pregnancy: Reexamining Guidelines. 2009;1:71\u2013110.","journal-title":"Natl Res Council: Weight Gain Dur Pregnancy: Reexamining Guidelines"},{"key":"8420_CR28","doi-asserted-by":"publisher","first-page":"E228","DOI":"10.1097\/AOG.0000000000002960","volume":"132","author":"ACOG Practice Bulletin No","year":"2018","unstructured":"ACOG Practice Bulletin No. 201: pregestational diabetes mellitus. Obstet Gynecol. 2018;132:E228\u201348.","journal-title":"Obstet Gynecol"},{"key":"8420_CR29","doi-asserted-by":"publisher","first-page":"E102","DOI":"10.1097\/AOG.0000000000002237","volume":"130","author":"YY El-Sayed","year":"2017","unstructured":"El-Sayed YY, Borders AEB, Gyamfi-Bannerman C. Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2017;130:E102\u20139.","journal-title":"Obstet Gynecol"},{"key":"8420_CR30","doi-asserted-by":"crossref","unstructured":"Munda A, Kovacic C. & Pongrac Barlovic, D. Real-world data on the minimed 780G advanced hybrid closed-loop system use during type 1 diabetes pregnancy: one centre observational study. J Diabetes Complications. 2024;38.","DOI":"10.1016\/j.jdiacomp.2024.108795"},{"key":"8420_CR31","doi-asserted-by":"publisher","unstructured":"Murphy HR. Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters. Diabetologia\u00a0, 2019;62: 1123\u20131128 Preprint at https:\/\/doi.org\/10.1007\/s00125-019-4904-3.","DOI":"10.1007\/s00125-019-4904-3"},{"key":"8420_CR32","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.2337\/dc25-0758","volume":"48","author":"JE Larsson","year":"2025","unstructured":"Larsson JE, et al. Sight-Threatening diabetic retinopathy during and after Pregnancy-A nationwide Matched-Cohort study. Diabetes Care. 2025;48:1837\u201343.","journal-title":"Diabetes Care"},{"key":"8420_CR33","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.2337\/dc24-1320","volume":"47","author":"K Beunen","year":"2024","unstructured":"Beunen K, et al. Advanced hybrid Closed-Loop therapy compared with standard insulin therapy intrapartum and early postpartum in women with type 1 diabetes: A secondary observational analysis from the CRISTAL randomized controlled trial. Diabetes Care. 2024;47:2002\u201311.","journal-title":"Diabetes Care"},{"key":"8420_CR34","unstructured":"National Pregnancy in Diabetes Audit - NHS England Digital NPID - detailed. Analysis 2021 and 2022. 2023 Cited 2024 Nov 7. Last access 20 Oct 2025 https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/national-pregnancy-in-diabetes-audit"},{"key":"8420_CR35","doi-asserted-by":"crossref","unstructured":"Scott E. M, et al.\u00a0Continuous Glucose Monitoring Metrics and Birthweight: Informing Management of Type 1 Diabetes throughout Pregnancy. Diabetes Care. 2022 Aug 1;45(8)1724\u20131734","DOI":"10.2337\/dc22-0078"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-025-08420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-025-08420-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-025-08420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:47:42Z","timestamp":1767066462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12884-025-08420-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8420"],"URL":"https:\/\/doi.org\/10.1186\/s12884-025-08420-3","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The case series adheres to the tenets of Good Clinical Practice and to the Declaration of Helsinki and received approval from the local ethics committee (number 183\/2025). Written informed consent was obtained from all women included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1356"}}